EP1 RECEPTOR ANTAGONIST BLOCKS THE DIARRHEAGENIC, BUT NOT CYTOPROTECTIVE, ACTIONS OF A SYNTHETIC PROSTAGLANDIN

被引:16
作者
LANTHORN, TH
BIANCHI, RG
PERKINS, WE
机构
[1] GD SEARLE & CO,NEUROL DIS RES,SKOKIE,IL 60077
[2] GD SEARLE & CO,INFLAMMATORY DIS RES,SKOKIE,IL 60077
关键词
EP1; RECEPTOR; CYTOPROTECTION; DIARRHEA; PROSTAGLANDINS; EP3;
D O I
10.1002/ddr.430340106
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Naturally occurring and synthetic prostaglandins acting at EP type receptors have a number of physiological actions, including cytoprotective and antisecretory effects, that are therapeutically useful. In addition they can produce other effects, such as diarrhea. It is possible that these actions are mediated by different EP receptor subtypes. The actions of a subtype-selective prostaglandin agonist has suggested that diarrhea is not due to activity at the EP3 receptor, while cytoprotection and antisecretory actions may be. The recent development of a bioavailable EP1 antagonist, SC-51089, has made it possible to examine this more directly. SC-30249, the active isomer of misoprostol, protects against indomethacin-induced gastric lesions and produces diarrhea in rats. SC-51089, ig, shifted the dose-response curve for SC-30249-induced diarrhea significantly to the right. ED,, values (assessed at 5 hr following administration of SC-30249) were 13.8 mu g/kg (0.036 mu mol/kg) for SC-30249 alone and 110.8 mu g/kg (0.290 mu mol/kg) for SC-30249 plus SC-51089. This antagonism of diarrhea was overcome by higher doses of SC-30249. SC-30249 dose-dependently inhibited gastric lesions induced by indomethacin (ED(50) = 3.4 mu g/kg, 0.009 mu mol/kg, ig). SC-51089 did not reduce the cytoprotective effects of SC-30249 (ED(50) = 1.1 mu g/kg, 0.003 mu mol/kg, ig, SC-30249 in combination with SC-51089). These results are consistent with the hypothesis that the EP1 receptor subtype mediates the diarrheagenic effect of EP receptor agonists, but not their cytoprotective actions. These results provide a mechanistic basis for cytoprotective prostaglandins with greatly reduced side effects. (C) 1995 Wiley-Liss, Inc.
引用
收藏
页码:35 / 38
页数:4
相关论文
共 10 条
  • [1] MISOPROSTOL PRECLINICAL PHARMACOLOGY
    BAUER, RF
    [J]. DIGESTIVE DISEASES AND SCIENCES, 1985, 30 (11) : S118 - S125
  • [2] BAUER RF, 1987, FED PROC, V46, pA4481
  • [3] COLEMAN RA, 1994, PHARMACOL REV, V46, P205
  • [4] N-SUBSTITUTED DIBENZOXAZEPINES AS ANALGESIC PGE(2) ANTAGONISTS
    HALLINAN, EA
    HAGEN, TJ
    HUSA, RK
    TSYMBALOV, S
    RAO, SN
    VANHOECK, JP
    RAFFERTY, MF
    STAPELFELD, A
    SAVAGE, MA
    REICHMAN, M
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1993, 36 (22) : 3293 - 3299
  • [5] STUDIES ON THE CHARACTERIZATION OF PROSTANOID RECEPTORS - A PROPOSED CLASSIFICATION
    KENNEDY, I
    COLEMAN, RA
    HUMPHREY, PPA
    LEVY, GP
    LUMLEY, P
    [J]. PROSTAGLANDINS, 1982, 24 (05): : 667 - 689
  • [6] PERKINS WE, 1994, J PHARMACOL EXP THER, V269, P151
  • [7] ANTISECRETORY, MUCOSAL-PROTECTIVE, AND DIARRHEOGENIC ACTIVITY OF A NOVEL SYNTHETIC PROSTAGLANDIN, SC-46275, IN THE RAT
    PERKINS, WE
    COLLINS, PW
    BIANCHI, RG
    GASIECKI, AF
    BAUER, RF
    JONES, PH
    GAGINELLA, TS
    [J]. DRUG DEVELOPMENT RESEARCH, 1991, 23 (04) : 349 - 358
  • [8] SANNER JH, 1969, ARCH INT PHARMACOD T, V180, P46
  • [9] SAVAGE MA, 1993, ESSENTIAL FATTY ACID, V49, P939
  • [10] INVITRO CHARACTERIZATION OF PROSTANOID EP-RECEPTORS IN THE NONPREGNANT HUMAN MYOMETRIUM
    SENIOR, J
    MARSHALL, K
    SANGHA, R
    BAXTER, GS
    CLAYTON, JK
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 1991, 102 (03) : 747 - 753